March 23, 2020 / 1:34 PM / 7 days ago

BRIEF-Esperion To Present Data From Late-Stage and Mid-Stage Trials Testing NEXLETOL™ And NEXLIZET™

March 23 (Reuters) - Esperion Therapeutics Inc:

* ESPERION ANNOUNCES POOLED ANALYSES FROM PHASE 3 LDL-C LOWERING DEVELOPMENT PROGRAM OF THE NEXLETOL™ (BEMPEDOIC ACID) TABLET AND PHASE 2 STUDY RESULTS OF THE NEXLIZET™ (BEMPEDOIC ACID AND EZETIMIBE) TABLET TO BE PRESENTED AT THE AMERICAN COLLEGE OF CARDIOLOGY’S 69TH ANNUAL SCIENTIFIC SESSION TOGETHER WITH WORLD CONGRESS OF CARDIOLOGY (ACC.20/WCC) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below